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Abstract. Desmopressin (dDAVP) is a safe haemostatic 
agent with previously reported antitumour activity. It acts 
as a selective agonist for the V2 vasopressin membrane 
receptor (V2r) present on tumour cells and microvasculature. 
The purpose of this study was to evaluate the novel peptide 
derivative [V4Q5]dDAVP in V2r-expressing preclinical mouse 
models of breast cancer. We assessed antitumour effects of 
[V4Q5]dDAVP using human MCF-7 and MDA-MB-231 breast 
carcinoma cells, as well as the highly metastatic mouse F3II 
cell line. Effect on in vitro cancer cell growth was evaluated 
by cell proliferation and clonogenic assays. Cell cycle distri-
bution was analysed by flow cytometry. In order to study 
the effect of intravenously administered [V4Q5]dDAVP on 
tumour growth and angiogenesis, breast cancer xenografts 
were generated in athymic mice. F3II cells were injected 
into syngeneic mice to evaluate the effect of [V4Q5]dDAVP 
on spontaneous and experimental metastatic spread. In vitro 
cytostatic effects of [V4Q5]dDAVP against breast cancer 
cells were greater than those of dDAVP, and associated with 
V2r-activated signal transduction and partial cell cycle arrest. 
In MDA-MB-231 xenografts, [V4Q5]dDAVP (0.3 µg/kg, thrice 
a week) reduced tumour growth and angiogenesis. Treatment 
of F3II mammary tumour-bearing immunocompetent mice 
resulted in complete inhibition of metastatic progression. 
[V4Q5]dDAVP also displayed greater antimetastatic efficacy 
than dDAVP on experimental lung colonisation by F3II cells. 
The novel analogue was well tolerated in preliminary acute 
toxicology studies, at doses ≥300-fold above that required 
for anti-angiogenic/antimetastatic effects. Our data establish 
the preclinical activity of [V4Q5]dDAVP in aggressive breast 
cancer, providing the rationale for further clinical trials.
Introduction
Desmopressin (1-deamino-8-D-arginine vasopressin or 
dDAVP) is a synthetic peptide derivative of the antidiuretic 
hormone used to boost the levels of clotting factors in certain 
haemostatic disorders (1). DDAVP differs from the natural 
peptide by deamination of cystein in position 1, which prolongs 
its half-life, and substitution of L-arginine by D-arginine in 
position 8, which reduces the pressor effect and confers selec-
tivity for the vasopressin type 2 membrane receptor (V2r) (2). 
This receptor subtype is present in kidney collecting ducts 
and endothelium (3,4). By acting on endothelial cells dDAVP 
induces a strong haemostatic effect causing the release of 
coagulation factor VIII, von Willebrand factor (VWF) and 
plasminogen activators from microvascular stores into the 
bloodstream (5). V2r expression was also reported in trans-
formed epithelial cells and several human tumour cell lines, 
including breast cancer (6,7). V2r stimulation in breast carci-
noma is associated with antiproliferative signalling, involving 
activation of adenylate cyclase followed by intracellular cAMP 
elevation (8).
Preclinical studies in mice showed that intravenous admin-
istration of dDAVP inhibited experimental lung metastases in 
a dose-dependent manner (9,10) and dramatically decreased 
locoregional and distant spread in a model of surgical 
manipulation of aggressive breast tumours (11). Hermo et al 
confirmed the beneficial effect of perioperative dDAVP on 
survival in dogs with advanced mammary cancer (12,13). As 
mentioned above, dDAVP drastically increases circulating 
levels of VWF by acting on V2r in endothelial cells. Terraube 
and collaborators showed that VWF plays a protective role 
against cancer cell dissemination and absence of VWF leads 
to increased metastatic potential (14). Additionally, our group 
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reported that dDAVP inhibited the early angiogenic response 
and markedly decreased vascularisation of growing subcu-
taneous tumours (15). Experimental evidence suggested that 
dDAVP reduces angiogenesis by inducing the formation of 
angiostatin, a potent inhibitor of angiogenesis that is gener-
ated by cancer-mediated proteolysis of plasminogen (16,17). 
Thus, dDAVP seems to produce a dual antimetastatic and 
anti-angiogenic effect, breaking the cooperative interplay of 
tumour and endothelial cells during disease progression (18). 
Taken together, dDAVP appears as a promising lead compound 
for the development of novel peptide analogues with enhanced 
anticancer efficacy. With this purpose, dDAVP (Fig. 1A) was 
rationally modified, and the novel analogue [V4Q5]dDAVP 
(1-deamino-4-valine-5-glutamine-8-D-arginine vasopressin) 
(Fig. 1B) was synthesized and assayed. Amino acid positions 4 
and 5 belong to the conformational peptide loop which has a 
key role in ligand-receptor interaction and antitumour activity 
(5,19-22). In an initial evaluation, [V4Q5]dDAVP exhibited a 
significantly higher cytostatic effect against breast cancer 
cells than the parental compound dDAVP and compared to 
other screened peptide derivatives (21). In the present study, 
we further characterized the anticancer activity of the novel 
analogue [V4Q5]dDAVP on V2r-expressing breast cancer 
preclinical models. The effect of the compound on xenograft 
tumour growth and angiogenesis was assessed. Additionally, 
we determined the efficacy of the novel analogue on metastatic 
progression in immunocompetent hosts.
Materials and methods
Cell lines and culture conditions. Human breast carcinoma 
cell lines MDA-MB-231 (ATCC HTB-26) and MCF-7 (ATCC 
HTB-22) were obtained from the American Type Culture 
Collection. MDA-MB-231 is a triple-negative breast cancer 
(TNBC) cell line which lacks the oestrogen receptor (ER) and 
progesterone receptor (PR), and expresses low levels of human 
epidermal growth factor receptor 2 (HER2)/neu. It also belongs 
to the claudin-low molecular subtype. MCF-7 is a ER-positive/
PR-positive luminal mammary carcinoma (23). The F3II 
mammary carcinoma cell line is a highly invasive and meta-
static variant derived from a clone of a spontaneous BALB/c 
mouse mammary tumour. It is a hormone-independent tumour 
cell line and express low levels of HER2/neu. Tumour cells were 
grown in Dulbecco's modified Eagle's medium (DMEM, Gibco, 
Rockville, MD, UsA) plus 10% fetal bovine serum (FBs), 2 mM 
glutamine and 80 µg/ml gentamycin in monolayer culture, at 
37˚C in a humidified atmosphere of 5% CO2. HMVEC-L human 
microvascular endothelial cell line was obtained from Cascade 
Biologics and cultured in gelatin coated plates using endothelial 
cell medium with specific growth factors (EGM-2 MV Bullet 
Kit, Lonza, Milan, Italy). All cells were harvested using a 
tripsin/EDTA solution (Gibco) diluted in phosphate-buffered 
saline (PBs).
Immunofluorescence detection of V2r. Briefly, cells were 
seeded on glass coverslips, and fixed with paraformaldehyde. 
After incubation with blocking agent, cells were incubated 
with a goat polyclonal anti-V2r antibody for 1 h at 37˚C (Santa 
Cruz Biotechnology, santa Cruz, CA, UsA). Receptor-bound 
antibodies were detected with a secondary rabbit poly-
clonal FITC-conjugated antibody (Chemicon International, 
Temecula, CA, UsA) and nuclei were labeled with DAPI 
(Vector Laboratories, Peterborough, UK). samples were 
examined using a TE-2000 microscope (Nikon Inc., Tokyo, 
Japan). MCF-7 cells were used as a positive control of V2r 
expression (6).
Peptide compounds and dosing. DDAVP and [V4Q5]dDAVP 
were synthesized in the solid phase, using Nα-Fmoc protec-
tion and the tea-bag strategy (21). Peptides were purified by 
reversed-phase high-performance liquid chromatography and 
quantified using a commercial dDAVP reference standard 
(BCN Peptides, Barcelona, spain).
Compounds were injected intravenously at 0.3 µg/kg, 
this being a clinically relevant dose of dDAVP with widely 
acknowledged haemostatic effects in humans (4), as well as 
antitumour properties in mice (10). since it is known that 
peptides such as dDAVP can induce tachyphylaxis with 
daily applications (3), compounds were administered on 
a thrice-weekly basis when treatment lasted for >5 days. In 
vitro experiments were performed using nanomolar and low 
micromolar concentrations of the peptides, a range consistent 
with the in vivo dosage (9,24).
Cell proliferation assay. Antiproliferative effect against rapidly 
growing tumour cells was measured using the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
(sigma-Aldrich, st. Louis, MO, UsA). Briefly, cells were 
plated in 96-well flat bottom plates at a density of 2.5x103 per 
200 µl in complete DMEM, allowed to attach overnight, and 
then treated with dDAVP or [V4Q5]dDAVP (100-1,500 nM) or 
vehicle for 72 h. Blockade of agonistic effect was achieved by 
incubation with the selective and competitive V2r antagonist 
tolvaptan (Otsuka Pharmaceutical Co., Tokyo, Japan). MTT 
reagent was added to each well and the plate incubated for 4 h. 
After solubilisation using dimethyl sulfoxide the absorbance 
of each well was measured at 570 nm. The optical density of 
untreated control cells was taken as 100% viability.
cAMP quantification. Briefly, carcinoma cells were stimulated 
with [V4Q5]dDAVP (1,000 nM) or saline vehicle for 1 h and 
intracellular cAMP levels were measured using the Cyclic 
AMP EIA kit (ACE, Cayman Chemical Co., Ann Arbor, MI, 
UsA) according to the manufacturer's instructions.
PKA activity. The effect of [V4Q5]dDAVP on PKA activity 
of MCF-7 total cell extract was determined by measuring 
the incorporation of [32P] orthophosphate from [32P]γ-ATP 
into PKA substrate histone H1. We tested the activity of the 
enzyme present in cells incubated for 30 min or 1 h with or 
without [V4Q5]dDAVP (1,000 nM) or 8-Br-cAMP (500 µM). 
8-Br-cAMP is a membrane-permeable analogue of cAMP 
and was used as a positive control of PKA activation. After 
treatment, cell cultures were washed with PBs, scraped into 
a buffer containing 25 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 
0.5 mM EGTA, 1 µg/ml leupeptin and 1 µg/ml aprotinine, and 
homogenized with a Pellet pestle motor homogenizer. This 
material was used for PKA activity determinations. Histone H1 
(0.5 µg/μl) was incubated with 35 µg of cellular protein in a 
reaction mixture consisting of 50 mM Tris-HCl, 10 mM 
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MgCl2, 100 µM ATP and 20 µCi of [32P]-ATP (200 µl of total 
volume). After 30 min of incubation, proteins were precipitated 
with 10% trichloroacetic acid, after adding bovine serum 
albumin (0.3 µg/µl), and then were centrifuged at 5,000 g for 
10 min. Precipitated proteins were spotted onto p81 Whatman 
paper, washed in 75 mM orthophosphoric acid and dried before 
counting the radioactivity in a β counter. Results are expressed 
by rate of PKA activity with or without cAMP (1 µM).
Clonogenic assay. Cytostatic effects of [V4Q5]dDAVP 
were also examined by the colony formation assay (22). 
MDA-MB-231 cells were grown in complete medium with 
dDAVP or [V4Q5]dDAVP (100-1,500 nM). Complete medium 
with tested peptides was renewed after 72 h. seven days after 
cell seeding, colonies of >50 cells were counted. The concen-
tration producing 50% inhibition (IC50) was determined by 
plotting a linear regression curve.
Determination of cell cycle. Cell cycle was evaluated by 
flow cytometry (25). After 48 h of starvation, MDA-MB-231 
cells were treated for 24 h with dDAVP or [V4Q5]dDAVP in 
complete medium and collected by trypsinization. Cells were 
then fixed in 70% chilled methanol for 30 min, treated with 
1 µg/ml RNase A (sigma-Aldrich) and stained with 100 µg/ml 
propidium iodide. Cell cycle phase distribution of nuclear DNA 
was carried out in a FACsCalibur cytometer using WinMDI 
2.9 software.
Endothelial cell morphogenesis assay. In vitro endothelial cell 
morphogenesis assay was performed using Matrigel-coated 
24-well plates (BD Biosciences, san Jose, CA, UsA) (15). 
Briefly, 1x105 HMVEC-L cells were incubated with dDAVP 
or [V4Q5]dDAVP at a concentration of 100 nM. After allowing 
capillary tube formation for 24 h, randomly chosen fields 
were photographed at magnification x100, and quantification 
was conducted. The number of capillary-like tubes formed in 
control cultures was taken as 100%.
Mice. Specific pathogen-free 8-week-old female BALB/c and 
athymic BALB/c (nu/nu) mice were purchased from UNLP 
(Universidad Nacional de La Plata, Buenos Aires, Argentina), 
and kept 5-8 mice per cage in our animal house facility at the 
National University of Quilmes. Food and water was provided 
ad libitum and general health status of the animals was 
Figure 1. Peptide sequence of [V4Q5]dDAVP and immunofluorescence detection of vasopressin type 2 receptor in breast cancer and microvascular endothelial 
cell lines. schematic view of (A) parental compound dDAVP (1-deamino-8-D-arginine vasopressin) and (B) novel analogue [V4Q5]dDAVP (1-deamino-
4-valine-5-glutamine-8-D-arginine vasopressin). Red shaded area indicates site of amino acid substitution belonging to the loop region of the peptide. Amino 
acid sequences are shown using the standard three-letter designations. Disulfide bonds between positions 1 and 6 are shown with connecting lines. Bold type 
text indicates modified amino acids in positions 4 and 5. (C) Detection of V2r expression by immunofluorescence. MDA-MB-231 human breast carcinoma 
cells, HMVEC-L human microvascular endothelial cells from lung, F3II mouse mammary carcinoma cells and MCF-7 human breast carcinoma cells (positive 
control) are shown. Magnification, x1,000.
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monitored daily. All protocols were approved by the National 
University of Quilmes institutional Animal Care Committee.
In vivo angiogenesis assays. To evaluate effects on MDA-MB-
231-induced angiogenesis, a modified Matrigel plug assay was 
conducted. A mixture containing 500 µl of Matrigel, heparin 
(50 U/ml) and 4.5x106 tumour cells was injected subcutane-
ously into BALB/c athymic mice. Treatment consisted of 
three weekly intravenous doses of dDAVP or [V4Q5]dDAVP 
(0.3 µg/kg).
Animals were sacrificed 14 days after cell injection. Plugs 
were recovered and scanned at high resolution. The extent 
of vascularisation was assessed by the amount of haemo-
globin detected in the implants using the Drabkin method 
(sigma-Aldrich). The mean optical density of plugs from 
control group was taken as 1 (relative haemoglobin content).
An intradermal angiogenesis assay was performed to test 
[V4Q5]dDAVP effect on early F3II tumour-induced vasculari-
sation (15). F3II cells (2x105) per site were inoculated in the 
flank of BALB/c mice in a DMEM and trypan blue solution. 
After 5 days, animals were sacrificed and skins were photo-
graphed. The vascular network around the tumour cell implant 
was quantified using a millimeter grid. Daily intravenous 
doses of dDAVP or [V4Q5]dDAVP (0.3 µg/kg) were adminis-
tered throughout the experiment.
Tumour progression. To generate breast cancer xenografts, a 
300-µl suspension containing 5x106 MDA-MB-231 cells in 
DMEM and Matrigel (1:1 volume ratio) was injected subcu-
taneously in BALB/c athymic mice. Tumours were measured 
periodically with a caliper and tumour volume was calculated 
by the formula: 0.52 x width2 x length. Treatment started 
14 days after MDA-MB-231 cell inoculation, when tumours 
reached volumes of ~50 mm3. DDAVP or [V4Q5]dDAVP 
(0.3 µg/kg) were administered intravenously thrice weekly. 
When the control group (saline vehicle) reached a mean 
tumour volume of 200 mm3 and exhibited signs of ulceration 
and necrosis, animals were photographed and tumours from 
different experimental groups were removed, fixed with 
formalin and routinely processed for haematoxylin and eosin 
(H&E) staining in order to examine tumour histology and 
vascularisation. The effect of [V4Q5]dDAVP on survival was 
also evaluated. Animals in saline vehicle or [V4Q5]dDAVP 
treated groups were euthanized by cervical dislocation when 
the humane tumour burden limits (>1,000 mm3) were reached 
(26). To generate tumours in immunocompetent hosts, 2x105 
F3II cells were injected subcutaneously in syngeneic BALB/c 
mice. Treatment started 7 days later, when tumours reached 
volumes of ~50 mm3. DDAVP or [V4Q5]dDAVP were admin-
istered as mentioned above. On day 50, F3II tumour-bearing 
animals were sacrificed and necropsied. To investigate the 
presence of spontaneous metastases, lungs were removed, 
fixed in Bouin's solution and macroscopic lung nodules were 
counted under a dissecting microscope.
Experimental lung metastases assay. To evaluate [V4Q5]dDAVP 
effect on blood-borne metastases, 2x105 F3II cells in DMEM 
were injected into the tail vein of mice (9). On day 21, lungs 
were excised, weighted, fixed in Bouin's solution, photographed 
and lung nodules were counted. DDAVP or [V4Q5]dDAVP 
were administered at 0.3 µg/kg in two intravenous doses, the 
first at time zero and the second 24 h after cell injection.
Toxicology studies. Acute toxicology studies were conducted 
at the National University of Litoral (Argentina). All proce-
dures were approved by the Institutional Ethics and security 
Committee and are consistent with the Guide for the Care and 
Use of Laboratory Animals (NRC 2011). Groups of 5 Wistar 
female rats received single intravenous doses of 1, 10 or 
100 µg/kg of [V4Q5]dDAVP or dDAVP. A full clinical evalu-
ation, including heart and respiratory rates, nervous system, 
motor activity, biochemical and haematological studies, was 
conducted at 1, 3, 6, 12, 24 and 72 h after drug administration. 
Body weight, food and water intake were monitored daily.
Statistical analysis. PRIsM 6, Version 6.01 (GraphPad 
software Inc., La Jolla, CA, UsA) was used to conduct all 
statistical analyses (IC50 values, one-way and two-way ANOVA 
and student's t-test). Tukey's multiple comparisons test was 
used after ANOVA analysis. In tumour progression protocols, 
growth rates represent the slopes of the linear regressions of 
the tumour volumes over time. In Kaplan-Meier plots, log-rank 
test and Cox regression analysis was applied to establish the 
association of treatment with survival. Differences were 
considered statistically significant at a level of P<0.05. Data 
are presented as mean ± sD or sEM.
Results
V2r expression in breast cancer and microvascular cells. 
Expression of V2r in MDA-MB-231 and F3II cells was first 
confirmed by immunofluorescence (Fig. 1C). MCF-7, a cell 
line known to display vasopressin membrane receptors (6), 
was used as a positive control of V2r expression. HMVEC-L 
cells were also positive for the V2r, as documented previously 
by reverse transcription-PCR (27).
Cytostatic effects of [V4Q5]dDAVP on human breast cancer 
cells. We evaluated the cytostatic effect of the novel analogue 
[V4Q5]dDAVP and the parental peptide dDAVP on log-phase 
growing breast cancer cells (Fig. 2A). After a 72-h expo-
sure, both peptides caused a mild reduction of proliferation 
in MCF-7 cell cultures (Fig. 2A, top). At concentrations 
>500 nM, [V4Q5]dDAVP treatment showed an enhanced cyto-
static effect compared to dDAVP, reducing cell proliferation 
by ≤26%. These results are consistent with a previous study, 
where several dDAVP peptide analogues, including [V4Q5]
dDAVP, were screened using MCF-7 cultures (21). Reduction 
of tumour cell proliferation by [V4Q5]dDAVP was associated 
with an activation of cAMP/PKA signalling axis. An increase 
in intracellular cAMP levels (Fig. 2B) and PKA activation 
(Fig. 2C) of nearly 90 and 40%, respectively, was observed 
after 60  min of incubation with [V4Q5]dDAVP. The cytostatic 
effect of the novel analogue was also evaluated in triple-
negative MDA-MB-231 cells. The antiproliferative profile 
of [V4Q5]dDAVP was similar to the one obtained against 
MCF-7 cells (Fig. 2A, bottom). Growth-modulating activity 
was completely abolished by the selective V2r antagonist 
tolvaptan, indicating that reduction of cell proliferation 
mainly results from V2r activation (Fig. 2A, bottom inset). 
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[V4Q5]dDAVP showed a much stronger effect on low density 
breast cancer cell cultures. MDA-MB-231 clonogenic growth 
was inhibited by 75% after 7-day treatment with 1,500 nM 
[V4Q5]dDAVP. Compared to parental peptide, novel analogue 
displayed an enhanced inhibitory effect on colony formation, 
with IC50 values of 1,130 and 1,440 nM for [V4Q5]dDAVP and 
dDAVP, respectively (Fig. 2D). Cell cycle distribution analysis 
showed that a 24-h treatment with [V4Q5]dDAVP (1,000 nM) 
resulted in partial arrest of MDA-MB-231 cells in G0/G1 
phase (Fig. 2E).
[V4Q5]dDAVP anticancer effects on human breast cancer 
xenografts. We next evaluated the novel analogue on 
MDA-MB-231 xenograft growth. Treatment with thrice weekly 
intravenous doses of [V4Q5]dDAVP for 8 weeks reduced final 
tumour load by 50% (Fig. 3A). Tumours grew at rates of 
2.95±0.56, 5.72±0.72 and 7.44±0.66 mm3/day (mean ± sD, 
P<0.001) in [V4Q5]dDAVP-treated, dDAVP-treated and 
control mice, respectively (Fig. 3B). In controls, xenografts 
grew by invading the subcutis and dermis, causing visible 
skin ulceration and necrosis. On the other hand, most animals 
treated with [V4Q5]dDAVP or dDAVP displayed preservation 
of superficial layers of skin, indicating inhibition of tumour 
infiltration and modulation of tumour aggressiveness (Fig. 3C). 
Histopathological studies of MDA-MB-231 xenografts from 
treated mice showed a decrease in tumour vascularisation 
(Fig. 3D). Quantification of intratumoural vascular density 
revealed a 30% reduction in the number of blood vessels in 
[V4Q5]dDAVP- and dDAVP-treated animals (Fig. 3E). As 
shown in the Kaplan-Meier curve, [V4Q5]dDAVP treatment 
was associated with increased survival (Fig. 3F).
Reduction of angiogenesis by [V4Q5]dDAVP. To further 
evaluate the efficacy on angiogenic response, a modified 
Matrigel plug assay was used. Thrice weekly intravenous 
doses of [V4Q5]dDAVP or dDAVP resulted in a decrease in 
MDA-MB-231 cell-induced angiogenesis (Fig. 4A). In addi-
tion, the highly aggressive mammary carcinoma F3II cell line 
was intradermally injected and used to assess the effect on 
early tumour-induced vascular development. After 5 days, F3II 
cells generated highly irregular and dense vascular networks 
around tumour cell implants in control animals. In [V4Q5]
Figure 2. Effect of [V4Q5]dDAVP on in vitro growth of human breast cancer cells. (A) Antiproliferative effect of dDAVP or [V4Q5]dDAVP on log-phase 
growing MCF-7 (upper panel) and MDA-MB-231 (lower panel) human breast carcinoma cells. Inset for MDA-MB-231, blockade of antiproliferative effect 
of [V4Q5]dDAVP (1,500 nM) by the selective and competitive V2r antagonist tolvaptan (1,500 nM). C, control; T, tolvaptan; VQ, [V4Q5]dDAVP and VQ+T, 
[V4Q5]dDAVP plus tolvaptan. (B) cAMP concentration in MCF-7 cells after 1 h of [V4Q5]dDAVP treatment. (C) PKA activity in MCF-7 cells treated with 
[V4Q5]dDAVP (1,000 nM) or the membrane-permeable cAMP analogue 8-Br-cAMP (500 nM), an activator of PKA. (D) Effect of dDAVP or [V4Q5]dDAVP 
treatment on clonogenic growth of MDA-MB-231 cells. Dotted line indicates 50% inhibition. (E) DNA-cell cycle analysis of MDA-MB-231 cells treated 
with [V4Q5]dDAVP (1,000 nM) for 24 h. In all cases, data are presented as mean ± sEM. Results are representative of at least three independent experiments. 
*P<0.05; **P<0.01; ***P<0.001 versus control. ##P<0.01; ###P<0.001 dDAVP versus [V4Q5]dDAVP. §§§P<0.001 [V4Q5]dDAVP plus tolvaptan versus [V4Q5]dDAVP 
alone.
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Figure 3. Effect of [V4Q5]dDAVP on tumour progression of human breast cancer xenografts. (A) MDA-MB-231 tumour volume in mice receiving saline vehicle 
(control), dDAVP or [V4Q5]dDAVP over time. (B) Growth rates of tumours from different experimental groups. (C) Representative photographs of nude mice 
bearing MDA-MB-231 xenografts. (D) Representative images of H&E stained tumour tissue sections. Magnification, x200. (E) Quantification of microvessel 
density. (F) Kaplan-Meier survival plot for vehicle- or [V4Q5]dDAVP-treated groups. Dotted line indicates 50% survival. Data are presented as mean ± sEM 
(tumour volume curve) or SD (growth rates and blood vessel quantification). n=5 or 6 animals per experimental group. Tumour growth results are representa-
tive of two independent experiments. *P<0.05; **P<0.01; ***P<0.001 versus control and ###P<0.001 [V4Q5]dDAVP versus dDAVP.
Figure 4. Effect of [V4Q5]dDAVP on in vitro and in vivo angiogenesis. (A) MDA-MB-231 cell-induced angiogenesis evaluated by a modified-Matrigel plug 
assay. Representative images of plugs recovered from vehicle, dDAVP or [V4Q5]dDAVP (0.3 µg/kg i.v.) treated mice are depicted. Relative haemoglobin content 
in Matrigel plugs was determined using the Drabkin's method. (B) In vivo microvessel density in BALB/c immunocompetent mice intradermally inoculated 
with F3II mammary carcinoma cells and treated with daily dDAVP or [V4Q5]dDAVP (0.3 µg/kg i.v.) for 5 days. Representative images of F3II tumour cell-
induced angiogenesis in different experimental groups. (C) Quantification of microvessel density around the F3II tumour cell implant. (D) Quantification 
of tube formation by HMVEC-L cells treated with dDAVP or [V4Q5]dDAVP. (E) Representative images of endothelial cell sprouting and tube formation. 
Magnification, x100. For in vivo experiments, n=5-7 animals per experimental group. Data are presented as mean ± SEM (tube formation assay) or ± SD 
(intradermal angiogenesis assay and Matrigel plug assay). *P<0.05; **P<0.01; ***P<0.001 versus control. #P<0.05 dDAVP versus [V4Q5]dDAVP.
INTERNATIONAL JOURNAL OF ONCOLOGY  46:  2335-2345,  2015 2341
dDAVP-treated mice, tumour angiogenesis was drastically 
inhibited, showing a vessel density reduction of ~50% (Fig. 4B 
and C). We also investigated direct effects of [V4Q5]dDAVP 
on microvascular endothelial cell morphogenesis (Fig. 4D 
and E). Twenty-four-hour incubation with [V4Q5]dDAVP 
reduced capillary-like tube formation by HMVEC-L cells. 
The parental peptide dDAVP did not displayed any significant 
effects on in vitro angiogenesis.
Effects of [V4Q5]dDAVP on metastasic progression of F3II 
mouse mammary tumours. We first evaluated the in vitro 
response to [V4Q5]dDAVP and dDAVP in log-phase growing 
hormone-independent F3II cells. Treatment during 72 h with 
both peptidic compounds caused a mild cytostatic effect in a 
concentration-dependent manner (Fig. 5A). We further tested 
the effects on progression of F3II tumours in BALB/c mice. 
Both dDAVP and [V4Q5]dDAVP treatments had limited 
impact on final tumour volume (1194±240, 1574.8±466.1 
or 1822.3±1185 mm3 in [V4Q5]dDAVP, dDAVP or control 
group, respectively, mean ± sD, P>0.05). Notwithstanding, 
tumours from [V4Q5]dDAVP-treated mice grew at a lower rate 
compared to tumours from animals administered with dDAVP 
or saline vehicle (Fig. 5B). All control animals displayed 
visible lung metastases, with a maximum of 6 macroscopic 
nodules per mouse. Remarkably, treatment with intravenous 
doses of [V4Q5]dDAVP for 6 weeks was able to completely 
abolish the formation of lung metastases (Fig. 5C). On the 
contrary, the effects of dDAVP on spontaneous metastases 
were not significant in the present experimental conditions.
Inhibition of experimental lung metastases by [V4Q5]dDAVP. 
F3II cells inoculated intravenously into BALB/c mice induce 
multiple macroscopic lung lesions after 3 weeks. Experimental 
lung colonisation by F3II cells was severely impaired after 
either dDAVP or [V4Q5]dDAVP treatment. However, whilst 
dDAVP reduced the number of lung nodules by 32%, the novel 
analogue [V4Q5]dDAVP displayed greater antimetastatic effi-
cacy, reducing by 62% the formation of metastases (Fig. 6A 
Figure 5. Effect of [V4Q5]dDAVP on tumour growth and spontaneous metastatic progression of subcutaneous mammary tumours. (A) Antiproliferative effect 
of dDAVP or [V4Q5]dDAVP on in vitro growth of V2r-expressing F3II cells. (B) After F3II tumours were generated in BALB/c immunocompetent mice, 
animals were treated with dDAVP or [V4Q5]dDAVP thrice a week (0.3 µg/kg i.v.). Tumour growth rates from day 11 onwards are shown. (C) spontaneous lung 
metastases quantification. For in vivo experiments, n=5 animals per experimental group. Data are presented as mean ± SEM (cell proliferation assay) or ± SD 
(tumour growth rates and spontaneous metastases). *P<0.05; **P<0.01; ***P<0.001 versus control and ###P<0.001 [V4Q5]dDAVP versus dDAVP.
Figure 6. Effect of [V4Q5]dDAVP on experimental lung colonisation by F3II mouse mammary carcinoma cells. (A) Number of metastatic lung nodules per 
mouse. (B) Representative left lung lobes (two from each group) are depicted. (C) Average lung weights corresponding to the different experimental groups. 
The dotted line represents the average pulmonary weight of healthy BALB/c mice described by Han et al (28). n=8 animals per experimental group. Data are 
presented as mean ± sD *P<0.05; **P<0.01; ***P<0.001 versus control. #P<0.05 [V4Q5]dDAVP versus dDAVP.
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and B). In addition, total lung weight was significantly reduced 
in [V4Q5]dDAVP-treated animals (Fig. 6C), with a weight 
close to healthy lung in BALB/c mice (28).
Toxicology studies. Preliminary acute toxicology studies 
conducted in Wistar rats revealed that intravenous administra-
tion of [V4Q5]dDAVP at doses of 1, 10 and 100 µg/kg had no 
influence on general symptoms, body weight, food and water 
consumption (Table I). These observations suggest that indi-
vidual injections are safe at doses ≥300-fold above that required 
for antiangiogenic/antimetastatic effects. Mild transient 
increases of glycemia and bilirubin were observed in treated 
groups. The other biochemical and haematological parameters 
were not significantly altered. DDAVP was administered as 
a reference standard, showing a safety profile consistent with 
previous observations (13,15).
Discussion
Vasopressin and its receptors were proposed as attractive 
targets for breast cancer therapy almost two decades ago, when 
vasopressin gene-related products were detected by immuno-
histochemistry as a feature of all breast cancer subtypes (29). 
selective agonists of V2 vasopressin membrane receptor, such 
as dDAVP, seem to evoke dual angiostatic and antimetastatic 
effects, breaking co-operative interactions of tumour and 
endothelial cells during tumour progression (18). Due to the 
interesting anticancer activity of dDAVP in animal studies 
(9,11,12,15), as well as its known haemostatic properties (3), 
a prospective, open-label phase II clinical trial is currently 
ongoing with the aim of assessing safety and preliminary anti-
cancer efficacy of perioperative use of dDAVP in breast cancer 
patients (NCT01606072). Peptides such as dDAVP are much 
appreciated as lead compounds for the development of new 
drugs with enhanced biological activity. In the present study, 
we characterized and compared the preclinical anticancer 
efficacy of the novel analogue [V4Q5]dDAVP with its parental 
peptide dDAVP. [V4Q5]dDAVP was originally selected from 
a panel of peptidic analogues derivatized from dDAVP with 
different sequence and structural modifications, mainly 
aiming at the N-terminal loop of the molecule. This search 
for more potent and selective V2r agonists included full-length 
nonapeptides, tetrapeptides and chiral isomers (21).
In the present study, in vitro studies exhibited moderate 
cytostatic activity of [V4Q5]dDAVP on log-phase growing 
human breast cancer cells, but showed a more potent inhibi-
tory effect on low density cell culture, with an IC50 value of 
1.13 µM. Chemical V2r blockade by tolvaptan completely 
abolished [V4Q5]dDAVP effects in MDA-MB-231 cells. These 
findings are in close agreement with the study by Keegan et al 
(30), where mild cytostatic effects of dDAVP on breast cancer 
cells were blocked by satavaptan, another non-peptidic V2r 
antagonist. Action of [V4Q5]dDAVP was associated with partial 
cell cycle arrest and normal V2r-activated signal transduction, 
involving intracellular cAMP elevation and PKA activation. 
Increases in cAMP intracellular levels using cAMP analogues 
or cAMP elevating agents, such as hormones or forskolin, can 
trigger cell cycle arrest or proapoptotic responses in numerous 
cancer cell types, including breast cancer (31-33). Consequently, 
several authors have postulated the adenylate cyclase/cAMP/
PKA axis as a growth suppressor system in breast cancer that 
could be targeted to block tumour formation (33,34).
Triple-negative breast cancer is defined by a lack of 
expression of both PR and ER, as well as a low expression of 
Table I. Acute toxicology study in Wistar rats after single intravenous doses of 1, 10 or 100 µg/kg of dDAVP or [V4Q5]dDAVP.
 Experimental groups ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Parametera Control dDAVP  dDAVP dDAVP [V4Q5]dDAVP [V4Q5]dDAVP [V4Q5]dDAVP
  1 µg/kg 10 µg/kg 100 µg/kg 1 µg/kg 10 µg/kg 100 µg/kg
Weightb (g) 218.3±8.7 234.2±8.1 240.3±9.4 241.8±16.8 225.4±16.8 226.0±10.9 225.8±6.1
Hematocritc (%) 39.3±4.0 40.4±2.3 40.5±2.7 41.8±3.4 40.0±1.6 41.0±2.2 41.2±1.7
RBC (106/ml) 5.1±0.5 5.2±0.3 5.5±0.3 5.7±0.3 5.6±0.2 5.4±0.5 5.5±0.2
WBC (103/ml) 4.8±0.4 4.8±0.3 4.4±0.5 4.1±0.7 4.2±0.2 4.5±0.3 4.7±0.7
Fibrinogenc (mg/dl) 198.3±44.8 221.0±67.8 226.7±48.4 243.0±63.1 206.0±56.7 210.0±41.8 179.5±45.7
Total proteinc (g/dl) 7.3±0.6 6.6±0.8 6.9±0.5 7.0±0.5 6.9±0.5 6.7±0.6 6.9±0.5
Direct bilirubin (mg/dl) 0.08±0.02 0.13±0.04 0.14±0.02d 0.17±0.03d 0.11±0.01d 0.12±0.02d 0.16±0.05d
Glucose (mg/dl) 179.9±4.1 207.0±25.7d 218.8±20.0d 230.7±12.1d 217.7±13.9d 221.1±19.7d 230.2±12.1d
Creatinine (mg/ml) 0.69±0.27 0.70±0.16 0.65±0.08 0.70±0.09 0.58±0.03 0.64±0.07 0.61±0.05
GGT (IU/l) 2.7±0.6 2.8±0.8 2.6±0.9 3.0±1.2 2.8±0.8 3.2±1.1 3.6±0.9
AsT (IU/l) 34.7±6.4 36.6±11.6 30.0±5.6 47.5±17.8 39.2±6.7 51.2±30.6 46.6±20.1
ALT (IU/l) 19.0±1.0 22.8±3.4 22.6±3.4 21.3±2.1 20.6±2.7 19.6±3.1 20.4±3.1
aToxicology parameters were measured 72 h after intravenous administration of the drugs unless stated otherwise. bBody weight was also 
monitored 24 and 48 h after drug injection. cFor haematocrit, fibrinogen and total protein measurements blood samples were also collected 
and analysed at 1, 3, 6, 10 and 24 h after intravenous administration of the drugs. No significant changes were observed between groups (data 
not shown). RBC, red blood cells; WBC, white blood cells; GGT, γ-glutamyl transpeptidase; AsT, aspartate aminotransferase; ALT, alanine 
aminotransferase. Values represent mean ± sD; and dP<0.05 (ANOVA). Number of rats per experimental group, 5-6.
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(HER2)/neu (35). There have been significant improvements 
in the outcome of other subtypes of breast cancer, including 
ER-positive/HER2 overexpressed tumours, attributed to 
the addition of targeted therapy, including hormonal agents 
and trastuzumab/pertuzumab (36,37). However, no targeted 
therapies are available for the treatment of triple-negative 
breast cancer, and frontline treatments are limited to surgical 
approaches and chemotherapeutics (38). In the present study we 
documented the efficacy of [V4Q5]dDAVP on triple-negative 
MDA-MB-231 breast cancer xenografts. Intravenous injection 
of clinically-relevant doses of [V4Q5]dDAVP caused a marked 
reduction in tumour growth and an increase in survival. 
Histological examination of xenografts also showed a signifi-
cant decrease in tumour angiogenesis in treated animals. In a 
previous study, our group reported that i.v. administration of 
dDAVP at doses of 2 µg/kg was able to significantly reduce 
intratumour vascularisation of F3II mammary tumours (15). 
DDAVP seems to modulate tumour angiogenesis by inducing 
the formation of angiostatin, a potent angiogenesis inhibitor that 
is generated by cancer-mediated proteolysis of plasminogen 
(16,17). Interestingly, an enhanced production of angiostatin by 
human mammary carcinoma cells was previously reported after 
incubation with [V4Q5]dDAVP compared to dDAVP-treated 
cells (39). Nevertheless, the possibility that other underlying 
mechanisms account for the antiangiogenic action of dDAVP 
or [V4Q5]dDAVP cannot be ruled out. systemic injection of 
dDAVP induces a rapid release of VWF by stimulation of V2r 
present in microvasculature. VWF is a large multimeric plasma 
glycoprotein that plays an essential role in primary haemostasis. 
This factor acts as a carrier for coagulation factor VIII and 
mediates platelet adhesion to endothelial cells (27,40). starke 
et al reported that loss of endothelial VWF by short interfering 
RNA results in increased in vitro angiogenesis. Additionally, 
VWF-deficient mice displayed increased mature blood vessel 
density, suggesting a potential role for VWF in the modula-
tion of angiogenesis (41). Other possible mechanism involves 
V2r-related signalling and actin. stimulation of V2r in endo-
thelial cells leads to activation of cAMP-mediated signalling, 
which plays a central role in actin cytoskeletal dynamics and 
cell migration (27,42,43). Interestingly, it has been reported that 
PKA activation suppresses endothelial cell migration in vitro 
and angiogenesis in vivo (44). The connection between the 
cAMP signalling pathway and actin structures could partially 
explain the direct effects of [V4Q5]dDAVP on HMVEC-L 
tube formation. However, the specific mechanisms responsible 
for [V4Q5]dDAVP effects on microvascular endothelial cells 
remain to be elucidated.
The F3II breast cancer cell line is invasive and metastatic, 
characterized by an aggressive hormone-independent growth 
and a low expression of (HER2)/neu, as revealed by immu-
nocytochemistry studies. In addition to angiostatic effects, 
[V4Q5]dDAVP treatment of immunocompetent mice bearing 
F3II tumours resulted in complete inhibition of metastatic 
progression. [V4Q5]dDAVP also showed an enhanced antimet-
astatic effect compared to dDAVP on experimental metastases 
to lung. As mentioned above, dDAVP causes the release of 
multimeric forms of VWF, reaching peak levels at 60-90 min 
after i.v. injection (4). Using VWF-deficient mice, Terraube 
et al demonstrated that the absence of VWF leads to increased 
metastatic potential of intravenously injected carcinoma cells. 
Furthermore, VWF was shown to directly induce apoptosis 
of tumour cells in vitro and caused death of metastatic cells 
arrested in the lungs (14,45). By modulating the interaction 
between cancer cells and subendothelial cells, VWF seems to 
reduce sustained adherence of tumour cells in the microvas-
culature at the target organ, thus inhibiting metastatic spread. 
More recently, it was found that aggressive breast and lung 
cancer cells with high levels of ADAM28 (a disintegrin and 
metalloproteinase 28) are able to avoid VWF-induced apop-
tosis at micrometastatic sites. ADAM28 binds and cleaves 
VWF, thus favoring the survival of metastatic cells in the tissue 
microenvironment (46). Taken together, these results suggest 
that VWF released after V2r stimulation plays a crucial role in 
resistance to blood-borne metastases.
Hydrophobicity enhancement at position 4 (glutamine by 
valine) and conservative substitution at position 5 (asparagine by 
glutamine) in [V4Q5]dDAVP resulted in an improved antitumour 
compound derived from dDAVP. The V2r is a transmembrane 
receptor that belongs to the G protein-coupled receptor family, 
having a deep cavity on the extracellular side containing 
hydrophobic moieties (19,20). Manning et al hypothesized that 
enhancing hydrophobicity at position 4 improves the interaction 
of vasopressin-related ligands with V2r (2). In a separate study, 
Manning and collaborators reported that 4-valine-dDAVP has 
a 10-fold higher affinity for the human V2r than dDAVP, with 
Ki values of 2.2 and 23.3 nM, respectevely (5). More recently, 
it was shown that, unlike dDAVP, 4-valine-dDAVP adminis-
tration was able to rescue the function of a mutated V2r in a 
pathological setting, displaying an enhanced agonistic potency 
on intracellular cAMP production without cross-reacting with 
other vasopressin receptor subtypes (47). In order to improve 
the stability of the analogue, we also introduced a conservative 
substitution at position 5, replacing asparagine with glutamine, 
based on its distinctive susceptibility to the deamidation 
process. Although both asparagine and glutamine are suscep-
tible to deamidation, deamidation of glutamine proceeds at a 
much slower rate than deamidation of asparagine at peptide 
level (48,49).
These rational modifications may favour ligand-receptor 
affinity by promoting hydrophobic interactions between the 
N-terminal conformational loop of [V4Q5]dDAVP and the amino 
acids located at the bottom of the V2r cavity. Enhancement of 
affinity between [V4Q5]dDAVP and V2r present in cancer and 
endothelial cells could result in augmented cAMP production 
and PKA activation, angiostatin generation and VWF release, 
thus explaining the increased biological activity of the peptidic 
analogue. Nevertheless, further pharmacological experiments 
should be performed to confirm stability, selectivity and 
potency of the novel compound.
In conclusion, compared to dDAVP, the novel analogue 
[V4Q5]dDAVP exhibited a significantly higher inhibitory effect 
on breast cancer cell proliferation and colony formation, as well 
as on MDA-MB-231 and F3II tumour growth. [V4Q5]dDAVP 
also displayed greater antimetastatic effects than dDAVP on 
spontaneous and experimental lung colonization.
While treatment for localised tumours has generally 
improved survival in the era of modern medicine, patients 
with advanced stage metastatic disease still suffer from a 
lack of effective therapies. Despite evident progress in overall 
mortality, the efficacy of adjuvant chemotherapy in reducing 
GARONA et al:  DEsMOPREssIN ANALOGUE [V4Q5]dDAVP IN BREAsT CANCER2344
metastatic risk has reached a plateau (50). Given that the 
benefit of chemotherapy is often mitigated by long-term side 
effects linked to a lack of selectivity (51-53), the potential 
combination with novel highly selective cytostatic agents 
such as [V4Q5]dDAVP is highly interesting. Preclinical effi-
cacy of the compound without overt toxicity supports further 
clinical development of [V4Q5]dDAVP as a novel adjuvant or 
maintenance therapy in aggressive and metastatic hormone-
independent breast cancer.
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